Preliminary clinical trial results of CD19/CD22 dual targeting CAR-T constructs showed efficiency in adult patients with acute lymphocytic leukaemia and diffused large B cell lymphoma (NCT00924326) (Hossain et al., 2018; Dai et al., 2019). Here, CD19 is linked to acute lymphoblastic leukemia.